The Department of Health and Human Services has unveiled the first set of Part B prescription drugs that will be subject to Medicare inflation rebates because they raised their prices faster than inflation.
Under prescription drug law, prescription drug companies have to pay back Medicare if they raise prices on seniors at a higher rate than inflation.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Joji Xavier
For comments and feedback: contact editorial@rttnews.com